Prostate-specific membrane antigen (PSMA) targeted PET is a new molecular imaging method for identifying and quantifying sites of prostate cancer disease, especially for detecting biochemical recurrences after initial therapy [16, 17]. This evidence concerns the gene FOLH1 and prostate carcinoma.